FY27 revenue growth of at least 15%
Management expects minimum 15% revenue growth in FY27, similar to FY26, with potential upside if global conditions improve.
ROSSARIBIOTECH / guidance tracker
Keep management guidance in view.
Rossari Biotech · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA margin of 12-13%
EBITDA margin expected to remain at current levels of 12-13% for FY27, with improvement from pharma and cost initiatives in H2.
Capex of ₹50-75 crore in FY27
Capital expenditure for FY27 planned at ₹50-75 crore, focused on Saudi facility and aroma chemicals.
Debt-free target in 18 months
Management aims to significantly reduce debt and become debt-free within 18 months through cash flows and non-core asset sales.